Actuate Therapeutics, Inc. (ACTU)
NASDAQ · Manufacturing · Pharmaceutical preparations
ACTU price, last 12 months
Key stats
- Previous close
- $0.2456
- Open
- $0.2148
- Day range
- $0.1741 – $0.2300
- 52-week range
- $0.1741 – $7.90
- Volume
- 3M
- Avg volume (20 days)
- 1.7M
- Market cap
- $6.9M
Performance
Technicals and fundamentals
About Actuate Therapeutics, Inc.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $6.9M